# The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial

NCT06871111

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 1 |
| **Sponsor** | University of Chicago |
| **Enrollment** | 24 participants |

## Key Eligibility Criteria

### Inclusion (11)

- Age 18 years or older
- Diagnosis of liver disease, liver failure, and/or cirrhosis
- All patients will be hospitalized and have a hepatology consult in place.
- They will be identified as having liver disease, liver failure, and/or cirrhosis based on a combination of at least one of the following:
- Labs demonstrating elevated liver chemistries (AST and ALT), elevated serum bilirubin levels, prolonged INR, or radiologic evidence of cirrhosis (e.g. nodular liver contour);

... and 6 more (see full listing online)

### Exclusion (39)

- MELD score \>30 at time of enrollment
- Patients receiving any antibiotics for treatment of an infection.
- Chronic or prophylactic antibiotic administration other than rifaximin, ciprofloxacin, or trimethoprim-sulfamethoxazole.
- Rifaximin will be either temporarily held or switched to another non-antibiotic therapy (e.g. lactulose or sodium benzoate) during the treatment phase of the trial. Potential subjects in whom the treating hepatologist deem it unsafe to pause or switch from Rifaximin therapy during the 7-10 day treatment phase will be excluded from the study.
- Patients who are currently admitted to the intensive care unit for vasoactive support or mechanical ventilation.

... and 34 more (see full listing online)

## Locations (1 total)

The University of Chicago Medical Center, Chicago, Illinois, United States